Silexion Therapeutics Q4 EPS $(1.40) Misses $(1.07) Estimate

Silexion Therapeutics (NASDAQ: SLXN) reported a Q4 loss of $(1.40) per share, missing the analyst consensus estimate of $(1.07) by 30.84%. This marks a significant decline of 100.66% compared to earnings of $213.60 per share in the same quarter last year.